


## PE/Cy7 anti-human CD134 (OX40)


<b>Catalog # / Size:</b>	2350060 / 100 tests
<b>Clone:</b>	Ber-ACT35 (ACT35)
<b>Isotype:</b>	Mouse IgG1, $\kappa$
<b>Immunogen:</b>	HTLV 1-transformed HUT 102 cells
<b>Reactivity:</b>	Human
<b>Preparation:</b>	The antibody was purified by affinity chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.
<b>Formulation:</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
<b>Concentration:</b>	Lot-specific



PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD4 FITC and OX-40 (clone Ber-ACT35) PE/Cy7 (top) or mouse IgG1,  $\kappa$  PE/Cy7 isotype control (bottom).

## Applications:

<b>Applications:</b>	Flow Cytometry
<b>Recommended Usage:</b>	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. <b>Test size products are transitioning from 20 microL to 5 microL per test.</b> Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



<b>Application Notes:</b>	Additional reported applications (for the relevant formats) include: Western blotting <sup>1</sup> , immunoprecipitation <sup>1</sup> , immunohistochemical staining <sup>2,3</sup> of paraffin embedded <sup>7</sup> and frozen tissue sections, ELISA <sup>4</sup> , and functional assay <sup>5</sup> . The LEAF™ or Ultra-LEAF™ purified antibody is recommended for functional assays (contact our <a href="#">custom solutions team</a> ).
---------------------------	--

<b>Application References:</b>	<ol style="list-style-type: none"> <li>1. Latza U, <i>et al.</i> 1994. <i>Eur. J. Immunol.</i> 24:677. (WB, IP)</li> <li>2. Durkop H, <i>et al.</i> 1995. <i>Brit. J. Haematol.</i> 91:927. (IHC)</li> <li>3. Durkop H, <i>et al.</i> 1997. <i>Brit. J. Haematol.</i> 98:863. (IHC)</li> <li>4. Willett B, <i>et al.</i> 2007. <i>J. Virol.</i> 81:9665. (ELISA)</li> <li>5. Li M and Zhang Y. <i>et al.</i> 2005. <i>Cell. Mol. Immunol.</i> 2:467. (FA)</li> <li>6. Gloviczki ML, <i>et al.</i> 2012. <i>Clin. J. Am. Soc. Nephrol.</i> 8:546. <a href="#">PubMed</a></li> <li>7. Domingos PL, <i>et al.</i> 2012. <i>An. Bras. Dermatol.</i> 87:851. (IHC)</li> </ol>
--------------------------------	--

---

**Description:** CD134, also known as OX40 and TNFRSF4, is a 50 kD type I transmembrane glycoprotein. It is a member of the TNF receptor family. OX40 is expressed on activated T lymphocytes including Th1, Th2, Th17, and Treg cells. The interaction of OX40 with OX40L results in B cell proliferation and antibody secretion, regulation of primary T cell expansion, and T cell survival. OX40 influences the size of the T cell memory pool and regulation of CD4<sup>+</sup> T cell tolerance.

**Antigen**  
**References:**

1. Smith CA, *et al.* 1994. *Cell*. 76:959.
2. Chen AL, *et al.* 1999. *Immunity*. 11:689.
3. Croft M. 2010. *Annu. Rev. Immunol.* 28:57.
4. Ruby CE, *et al.* 2009. *J. Immunol.* 183:5079